CTAs are priority targets for tumor immunotherapies because of their immunogenicity and tumor specificity [28], and recombinant tumor vaccines, such as MAGE-A3 antigen, have been used in clinical trials of lung cancer treatment [29]. The gene discussed is MAGEA3; the disease is neoplasm.